Health Topics — Immune & Antimicrobial
CBG and Antimicrobial Research: Antibacterial and Antifungal Signals
Two research threads — an MRSA finding with both in vitro and in vivo mouse model evidence, and earlier Candida biofilm research — what each has established and why neither constitutes evidence of clinical antimicrobial efficacy.
CBG's antibacterial activity against drug-resistant pathogens is one of the more striking findings in its preclinical research portfolio — and unlike most findings in this archive, it extends beyond the laboratory dish into a living organism. The Farha et al. (2020) study includes both in vitro and in vivo mouse model evidence against MRSA, which places this finding on a different tier than the in vitro-only work that characterizes most of the cannabinoid antimicrobial literature. The finding is real, the mechanism is identified, the mouse data is meaningful, and the distance from a mouse model to a clinical antibiotic remains large. All three things are true simultaneously.
Why Antimicrobial Research Requires Particular Care
Antimicrobial resistance — the growing inability of existing antibiotics to kill bacterial pathogens — is one of the most serious challenges in contemporary medicine. Drug-resistant infections kill hundreds of thousands of people annually, and the pipeline for new antibiotics has been historically thin relative to the scale of the problem. Against this backdrop, any finding of antibacterial activity in a novel compound attracts legitimate scientific interest and, reliably, disproportionate popular coverage.
The compliance risk of antimicrobial framing is specific and worth stating before the research is presented: a reader who concludes from this article that taking a CBG preparation protects against bacterial or fungal infection would be drawing a conclusion the evidence does not support, and acting on that conclusion in place of appropriate medical care could cause real harm. In vitro antibacterial activity — killing bacteria in a laboratory dish — does not establish that a compound kills bacteria in a living human body at achievable concentrations through any available route of administration. That translation has failed for many compounds with strong in vitro profiles. This article presents what the research has found, not what it means for infection prevention or treatment.
Thread One — The Antibacterial Signal: MRSA and the Farha Study
Methicillin-resistant Staphylococcus aureus — MRSA — is a bacterial strain that has developed resistance to most beta-lactam antibiotics, the class that includes penicillin and methicillin, through acquisition of an altered penicillin-binding protein that the antibiotics cannot effectively target. MRSA infections range from skin and soft tissue infections to life-threatening pneumonia, sepsis, and endocarditis, and are particularly dangerous in healthcare settings where vulnerable patients encounter the pathogen. New agents active against MRSA are a genuine clinical priority.
Study Design: In vitro screening study conducted at McMaster University as part of a broader cannabinoid antibacterial survey. Multiple cannabinoids were tested against a panel of gram-positive bacterial strains including multiple MRSA clinical isolates — bacteria taken from actual patient infections, not laboratory-adapted reference strains. Minimum inhibitory concentrations (MIC) were determined for each cannabinoid-bacteria pair.
CBG Findings: CBG demonstrated potent antibacterial activity against all MRSA strains tested, with MIC values in the low microgram-per-milliliter range — a level of potency considered clinically meaningful for comparison purposes, though in vitro MIC values do not translate directly to human dosing requirements. CBG was among the most active cannabinoids tested against gram-positive bacteria, outperforming CBD and CBC against MRSA specifically.
Mechanism Identified: The Farha group investigated how CBG kills bacteria rather than simply documenting that it does. Their evidence pointed to disruption of the bacterial cell membrane — CBG interferes with the integrity of the lipid membrane that surrounds gram-positive bacteria, compromising the membrane's ability to maintain the electrochemical gradients bacteria require for energy production and ion transport. This membrane disruption mechanism is distinct from how most conventional antibiotics work, which is significant: bacteria that have developed resistance to existing antibiotics through target modification may remain susceptible to membrane-disrupting agents.
In Vivo Mouse Model: The Farha study extended beyond cell culture to a mouse model of MRSA infection — a critical step that most cannabinoid antimicrobial research has not taken. In mice with systemic MRSA infection, CBG reduced bacterial loads by approximately 2.8 orders of magnitude, a reduction comparable in magnitude to vancomycin, the last-resort antibiotic used for serious MRSA infections when other options have failed. This in vivo finding — CBG performing comparably to vancomycin in a living animal — is what elevates this finding above the purely in vitro tier. It establishes that CBG can reduce bacterial burden in a living system, not only in isolated cell cultures. It does not establish that CBG is a viable clinical antibiotic or that it performs equivalently to vancomycin in human infections, where pharmacokinetics, dosing routes, and the complexity of human physiology introduce variables the mouse model does not capture.
Synergy with Bacitracin: A particularly notable finding was that CBG and bacitracin — a topical antibiotic used for skin infections — showed synergistic activity against MRSA. Combining sub-inhibitory concentrations of both compounds produced antibacterial effects greater than either alone. Synergistic combinations are of clinical interest because they may allow lower doses of established antibiotics while maintaining efficacy, potentially reducing toxicity and the selection pressure that drives resistance development.
Gram-Negative Limitation: CBG showed little activity against gram-negative bacteria — pathogens including E. coli, Salmonella, and Pseudomonas. Gram-negative bacteria have an outer membrane that acts as an additional barrier, and most of the cannabinoids tested were inactive against them. CBG's antibacterial activity is gram-positive selective, which defines the scope of its potential relevance significantly.
The In Vitro to Clinical Gap — Applied to Antibiotics
The history of antibacterial drug development illustrates the translation gap with particular clarity. Many compounds have demonstrated potent MRSA activity in vitro and failed to become clinical antibiotics — for reasons of systemic toxicity, inadequate bioavailability at infected tissue sites, rapid metabolism, or inability to achieve effective concentrations without causing harm to the host. An in vitro MIC value tells you what concentration kills bacteria in a dish. It tells you nothing about whether that concentration is achievable in blood, skin, lung, or bone tissue through an oral, topical, or intravenous dose, nor whether that concentration is tolerated by a human at the doses required.
The Specific Translation Question for CBG
CBG's oral bioavailability is limited and variable. The Farha mouse model established that CBG can reduce MRSA bacterial loads in a living animal at the doses used in that study — but the route of administration, the concentrations achieved, and the pharmacokinetics in that mouse model are not directly comparable to what is achievable through oral or topical use of a whole-plant hemp preparation in a human being. Whether CBG reaches skin tissue — the most plausible site of relevance given the MRSA skin infection context and the bacitracin synergy finding — at concentrations comparable to those active in the Farha study has not been examined in humans. No human clinical data on CBG's antibacterial activity exists as of 2026.
A 2026 study in ACS Omega (Mandal et al.) synthesized 26 CBG and CBGA derivatives and found that modifications to the terpene chain — lengths between 6 and 13 carbons — produced potent antibacterial activity against gram-positive strains including MRSA and vancomycin-resistant Enterococcus, with no detectable toxicity to mammalian cells. This is a structure-activity study of synthesized derivatives, not of naturally occurring CBG from hemp. It establishes that the CBG molecular scaffold is a promising platform for antibiotic development research — it does not change what whole-plant CBG preparations contain or how they behave.
Thread Two — The Antifungal Signal: Candida and Biofilm Research
The antifungal research thread is earlier, thinner, and requires more careful handling than the antibacterial thread. Candida species — particularly Candida albicans — are common fungal pathogens responsible for oral thrush, vaginal yeast infections, and in immunocompromised patients, potentially life-threatening systemic infections. Candida's ability to form biofilms — structured communities of cells embedded in a protective matrix that adheres to surfaces including medical devices and tissue — contributes significantly to its clinical persistence and resistance to antifungal treatment.
The Honest Evidence Summary — Both Threads
CBG's antibacterial activity against MRSA is the more substantive of the two findings: a well-designed study with both in vitro and in vivo mouse model components, a specific membrane disruption mechanism, in vivo bacterial load reductions comparable to vancomycin, gram-positive selectivity, and a notable synergy finding with bacitracin. The in vivo mouse finding places this on a different evidence tier than the purely in vitro cannabinoid antimicrobial research — it is the only finding in the CBG antimicrobial literature that has been tested in a living organism. It does not establish that CBG prevents or treats bacterial infections in humans. The route from a mouse model to a clinical antibiotic is long and most candidates fail it. CBG has not been tested in human infectious disease contexts.
The antifungal thread is an earlier in vitro signal with a less characterized mechanism and no animal or human follow-up as of 2026. It is recorded here because it exists and has been replicated in multiple laboratory studies. The distance from Candida biofilm inhibition in cell culture to a treatment or prevention claim for fungal infections is the full length of the translational pipeline — which, in this research domain, has not been traveled.
References
- Farha, M.A., El-Halfawy, O.M., Gale, R.T., et al. (2020). Uncovering the hidden antibiotic potential of cannabis. ACS Infectious Diseases, 6(3), 338–346. DOI: 10.1021/acsinfecdis.9b00419 [In vitro + in vivo mouse model; CBG reduced MRSA bacterial loads by ~2.8 orders of magnitude, comparable to vancomycin.]
- Appendino, G., Gibbons, S., Giana, A., et al. (2008). Antibacterial cannabinoids from Cannabis sativa: A structure-activity study. Journal of Natural Products, 71(8), 1427–1430.
- Blaskovich, M.A.T., Kavanagh, A.M., Elliott, A.G., et al. (2021). The antimicrobial potential of cannabidiol. Communications Biology, 4, 7.
- Feldman, M., Sionov, R.V., Smoum, R., et al. (2021). Comparative evaluation of inhibitory activities of cannabidiol and cannabigerol on the formation and development of Candida albicans biofilm. International Journal of Molecular Sciences, 22(16), 8770.
- Nissen, L., Zatta, A., Stefanini, I., et al. (2010). Characterization and antimicrobial activity of essential oils of industrial hemp varieties. Fitoterapia, 81(5), 413–419.
- Sharma, R., Martins, N., Kuca, K., et al. (2020). Chyawanprash: A traditional Indian bioactive health supplement. Biomolecules, 9(5), 161. [cited for cannabinoid biofilm context]
- Mandal, S., et al. (2026). Structure-activity relationships of cannabigerol and cannabigerolic acid derivatives as antibacterial agents against gram-positive bacteria. ACS Omega. DOI: 10.1021/acsomega.6c00126 [Synthesized derivatives only — not naturally occurring CBG. Terpene chain lengths 6–13 carbons showed potent activity against MRSA and VRE with no detectable mammalian cytotoxicity.]
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.